Review



mito rbcs  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Santa Cruz Biotechnology mito rbcs
    a, Confocal images (left) and quantification (right) of classical Mo isolated from JDM and SLE patients. Each dot represents the average count from at least ten different micrscopy fields from a study participant sample that was processed, stained and analyzed independently. Scale bar: 20 µm. b, Percentage of IL-1β − MxA + Mo and IL-1β + MxA + Mo in SLE patients without (blue, n=8) or with (red, n=6) circulating <t>Mito</t> + <t>RBCs.</t> c, Confocal images of classical Mo isolated from SLE patients showing evidence of erythrophagocytosis. GPA: Glycophorin A. Scale bar: 20 µm. d, Two-tailed Pearson’s correlation between SLEDAI and the percentage of IL-1β + ISGs + Mo (n=20). Dashed lines represent 95% confidence intervals. Each dot represents a study participant sample that was processed, stained and analyzed independently.
    Mito Rbcs, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 416 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mito+rbcs/MG-132/bio_rxiv__2023__08__03__551696-216-3-13
    Average 96 stars, based on 416 article reviews
    mito rbcs - by Bioz Stars, 2026-11
    96/100 stars

    Images

    1) Product Images from "An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes"

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    Journal: bioRxiv

    doi: 10.1101/2023.08.03.551696

    a, Confocal images (left) and quantification (right) of classical Mo isolated from JDM and SLE patients. Each dot represents the average count from at least ten different micrscopy fields from a study participant sample that was processed, stained and analyzed independently. Scale bar: 20 µm. b, Percentage of IL-1β − MxA + Mo and IL-1β + MxA + Mo in SLE patients without (blue, n=8) or with (red, n=6) circulating Mito + RBCs. c, Confocal images of classical Mo isolated from SLE patients showing evidence of erythrophagocytosis. GPA: Glycophorin A. Scale bar: 20 µm. d, Two-tailed Pearson’s correlation between SLEDAI and the percentage of IL-1β + ISGs + Mo (n=20). Dashed lines represent 95% confidence intervals. Each dot represents a study participant sample that was processed, stained and analyzed independently.
    Figure Legend Snippet: a, Confocal images (left) and quantification (right) of classical Mo isolated from JDM and SLE patients. Each dot represents the average count from at least ten different micrscopy fields from a study participant sample that was processed, stained and analyzed independently. Scale bar: 20 µm. b, Percentage of IL-1β − MxA + Mo and IL-1β + MxA + Mo in SLE patients without (blue, n=8) or with (red, n=6) circulating Mito + RBCs. c, Confocal images of classical Mo isolated from SLE patients showing evidence of erythrophagocytosis. GPA: Glycophorin A. Scale bar: 20 µm. d, Two-tailed Pearson’s correlation between SLEDAI and the percentage of IL-1β + ISGs + Mo (n=20). Dashed lines represent 95% confidence intervals. Each dot represents a study participant sample that was processed, stained and analyzed independently.

    Techniques Used: Isolation, Staining, Two Tailed Test

    a, Phagocytosis of CFSE-labeled RBCs in the presence or absence of IgG opsonizing antibodies. b, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by blood Mo. (n=3). c, Immunoblot analysis of whole cell lysate (WCL) and supernatants (Sup) from blood Mo that were treated as described. One representative of two experiments. d, Levels of IP-10 and IL-1β in the supernatants of bone marrow (BM) Mo cultured with media, Mito - or Mito + opsonized RBCs. (n=3). e, Phenotype of BLaER1 cells before (Day 1) and after (Day 6) differentiation into BLaER1 Mo. f, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by BLaER1 Mo. (n=3). g, Immunoblot analysis of WCL and Sup from BLaER1 Mo that were treated as described. One representative of two. h, Relative mtDNA abundance in Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. (n=3). i, Quantification of phagocytosis of CFSE-labeled Mito + RBCs RBCs generated with vehicle or EtBr (ρ 0 ). (n=3). j, Western blot analysis of Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. One representative of two.
    Figure Legend Snippet: a, Phagocytosis of CFSE-labeled RBCs in the presence or absence of IgG opsonizing antibodies. b, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by blood Mo. (n=3). c, Immunoblot analysis of whole cell lysate (WCL) and supernatants (Sup) from blood Mo that were treated as described. One representative of two experiments. d, Levels of IP-10 and IL-1β in the supernatants of bone marrow (BM) Mo cultured with media, Mito - or Mito + opsonized RBCs. (n=3). e, Phenotype of BLaER1 cells before (Day 1) and after (Day 6) differentiation into BLaER1 Mo. f, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by BLaER1 Mo. (n=3). g, Immunoblot analysis of WCL and Sup from BLaER1 Mo that were treated as described. One representative of two. h, Relative mtDNA abundance in Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. (n=3). i, Quantification of phagocytosis of CFSE-labeled Mito + RBCs RBCs generated with vehicle or EtBr (ρ 0 ). (n=3). j, Western blot analysis of Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. One representative of two.

    Techniques Used: Labeling, Western Blot, Cell Culture, Generated

    a, Heat map of differentially expressed genes in blood Mo that phagocytized either Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . b, Levels of IP-10 and IL-1β in the supernatants of blood Mo cultured with media, Mito - or Mito + RBCs. (n=6). c, Heat map of differentially expressed genes in BLaER1 Mo that phagocytized Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . d, Levels of IP-10 and IL-1β in the supernatants of BLaER1 Mo cultured with media, Mito - or Mito + RBCs. (n=4). e, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo activated with Mito + RBCs generated in the presence of vehicle, ethidium bromide (EtBr; ρ 0 ) or chloramphenicol (CAM). (n=4).
    Figure Legend Snippet: a, Heat map of differentially expressed genes in blood Mo that phagocytized either Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . b, Levels of IP-10 and IL-1β in the supernatants of blood Mo cultured with media, Mito - or Mito + RBCs. (n=6). c, Heat map of differentially expressed genes in BLaER1 Mo that phagocytized Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . d, Levels of IP-10 and IL-1β in the supernatants of BLaER1 Mo cultured with media, Mito - or Mito + RBCs. (n=4). e, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo activated with Mito + RBCs generated in the presence of vehicle, ethidium bromide (EtBr; ρ 0 ) or chloramphenicol (CAM). (n=4).

    Techniques Used: Cell Culture, Generated

    a, Normalized IP-10 levels in the supernatants of Mito + RBCs-activated wild type, cGAS KOor STING1 KO BLaER1 Mo. (n=3). b, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or Caspase-1 KO BLaER1 Mo. (n=3). c, Experimental scheme (left), dot/Western blot analysis (middle) and quantification (left; n=3) of Mito + RBCs (1 - 3) or BLaER1 Mo (2 − 4) labeled with bromodeoxyuridine (BrdU) and then immunoprecipitated (IP) with cGAS or NLRP3 antibodies. As a loading control, cGAS or NLRP3 immunoblot or double-stranded DNA (dsDNA) dot blot (DB) was performed. A.U.: Arbitrary Units.
    Figure Legend Snippet: a, Normalized IP-10 levels in the supernatants of Mito + RBCs-activated wild type, cGAS KOor STING1 KO BLaER1 Mo. (n=3). b, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or Caspase-1 KO BLaER1 Mo. (n=3). c, Experimental scheme (left), dot/Western blot analysis (middle) and quantification (left; n=3) of Mito + RBCs (1 - 3) or BLaER1 Mo (2 − 4) labeled with bromodeoxyuridine (BrdU) and then immunoprecipitated (IP) with cGAS or NLRP3 antibodies. As a loading control, cGAS or NLRP3 immunoblot or double-stranded DNA (dsDNA) dot blot (DB) was performed. A.U.: Arbitrary Units.

    Techniques Used: Western Blot, Labeling, Immunoprecipitation, Control, Dot Blot

    a, Western blot analysis confirming CRISPR/Cas9-mediated KO of cGAS and STING1. b, Normalized IP-10 levels in the supernatants of Mito + RBC-activated BLaER1 Mo in the presence of the cGAS inhibitor RU.521 or the STING inhibitor H151. (n=3). c, Western blot analysis of phosphorylated TBK1 and IRF3 in BLaER1 Mo cultured with media or Mito + RBCs. d, Western blot analysis confirming CRISPR/Cas9-mediated KO of AIM2. e, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or AIM2 KO BLaER1 Mo. (n=3). f, Flow cytometry analysis showing the internalization of unlabeled (control) or AlexaFluor 488 (AF488)-labeld IgG upon electroporation. g, Percentages of cell death measured by 7AAD incorporation. h, Western blot analysis confirming Trim-Away knockdown of AIM2 (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of AIM2 (right). (n=3). i, Western blot analysis confirming CRISPR/Cas9-mediated KO of Caspase-1. j, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated BLaER1 Mo in the presence of the NLRP3 inhibitor MCC950 or the caspase-1 inhibitor Ac-YVAD-cmk. (n=4). k, Phagocytosis of CFSE-labeled RBCs in wild type, cGAS KO, STING1 KO or caspase-1 KO BLaER1 Mo. (n=3).
    Figure Legend Snippet: a, Western blot analysis confirming CRISPR/Cas9-mediated KO of cGAS and STING1. b, Normalized IP-10 levels in the supernatants of Mito + RBC-activated BLaER1 Mo in the presence of the cGAS inhibitor RU.521 or the STING inhibitor H151. (n=3). c, Western blot analysis of phosphorylated TBK1 and IRF3 in BLaER1 Mo cultured with media or Mito + RBCs. d, Western blot analysis confirming CRISPR/Cas9-mediated KO of AIM2. e, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or AIM2 KO BLaER1 Mo. (n=3). f, Flow cytometry analysis showing the internalization of unlabeled (control) or AlexaFluor 488 (AF488)-labeld IgG upon electroporation. g, Percentages of cell death measured by 7AAD incorporation. h, Western blot analysis confirming Trim-Away knockdown of AIM2 (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of AIM2 (right). (n=3). i, Western blot analysis confirming CRISPR/Cas9-mediated KO of Caspase-1. j, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated BLaER1 Mo in the presence of the NLRP3 inhibitor MCC950 or the caspase-1 inhibitor Ac-YVAD-cmk. (n=4). k, Phagocytosis of CFSE-labeled RBCs in wild type, cGAS KO, STING1 KO or caspase-1 KO BLaER1 Mo. (n=3).

    Techniques Used: Western Blot, CRISPR, Cell Culture, Flow Cytometry, Control, Electroporation, Knockdown, Labeling

    a, Normalized cytokine levels in the supernatants of blood Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. b, Normalized cytokine levels in the supernatants of Mito + RBC-activated blood Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3). c, Normalized cytokine levels in the supernatants of BM Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. d, Normalized cytokine levels in the supernatants of Mito + RBCs-activated BM Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3).
    Figure Legend Snippet: a, Normalized cytokine levels in the supernatants of blood Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. b, Normalized cytokine levels in the supernatants of Mito + RBC-activated blood Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3). c, Normalized cytokine levels in the supernatants of BM Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. d, Normalized cytokine levels in the supernatants of Mito + RBCs-activated BM Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3).

    Techniques Used: Generated

    a, Western blot analysis of cytosolic fraction obtained from media, Mito + RBCs- or dsDNA/Lyovec-activated BLaER1 Mo. WCL: whole cell lysate. Quantification of lactate dehydrogenase (LDH) release (b) or propidium iodide (PI) internalization (c) in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec over time. Data are normalized to media-treated cells. (n=3). d, Western blot analysis of ASC oligomers (pyroptosome) formation in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec for 18 h. Triton X-100 soluble (TX100 Sol ) and insoluble (TX100 Ins ) fractions were immunoblotted with ASC antibody. One representative of two experiments. e, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of the lysosmal acidification inhibitor Bafilomycin A1 (BAf A1). (n=3). f, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of extracellular K + . (n=3).
    Figure Legend Snippet: a, Western blot analysis of cytosolic fraction obtained from media, Mito + RBCs- or dsDNA/Lyovec-activated BLaER1 Mo. WCL: whole cell lysate. Quantification of lactate dehydrogenase (LDH) release (b) or propidium iodide (PI) internalization (c) in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec over time. Data are normalized to media-treated cells. (n=3). d, Western blot analysis of ASC oligomers (pyroptosome) formation in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec for 18 h. Triton X-100 soluble (TX100 Sol ) and insoluble (TX100 Ins ) fractions were immunoblotted with ASC antibody. One representative of two experiments. e, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of the lysosmal acidification inhibitor Bafilomycin A1 (BAf A1). (n=3). f, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of extracellular K + . (n=3).

    Techniques Used: Western Blot

    a, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo, generated in the presence of vehicle, EtBr (ρ 0 ) or CAM and activated with Mito + RBCs. (n=4). b, Relative levels of mtDNA-encoded genes in cGAS (left) or NLRP3 (right) immunocomplexes isolated from Mito + RBC-activated wild type or MAVS KO BLaER1 Mo. (n=3). c, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo cultured with Mito + RBCs generated in the presence of Actinomycin D (Act D). (n=4). d, Normalized IL-1β levels in the supernatants of Mito + RBCs- or Poly I:C/Lyovec-activated wild type, MAVS KO or RIG- I/MDA5 KO BLaER1 Mo. (n=3).
    Figure Legend Snippet: a, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo, generated in the presence of vehicle, EtBr (ρ 0 ) or CAM and activated with Mito + RBCs. (n=4). b, Relative levels of mtDNA-encoded genes in cGAS (left) or NLRP3 (right) immunocomplexes isolated from Mito + RBC-activated wild type or MAVS KO BLaER1 Mo. (n=3). c, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo cultured with Mito + RBCs generated in the presence of Actinomycin D (Act D). (n=4). d, Normalized IL-1β levels in the supernatants of Mito + RBCs- or Poly I:C/Lyovec-activated wild type, MAVS KO or RIG- I/MDA5 KO BLaER1 Mo. (n=3).

    Techniques Used: Generated, Isolation, Cell Culture

    a, Western blot analysis confirming CRISPR/Cas9-mediated KO of mitochondrial DNA polymerase gamma (POLG; Polγ). b, Normalized IL-1β levels in the supernatants of Mito + RBC-activated wild type or POLG KO BLaER1 Mo. (n=3). c, DB analysis of cGAS or NLRP3 immunocomplexes isolated from Mito + RBCs-activated BLaER1 Mo. As a loading control, dsDNA dot blot (DB) was performed. d, 8-OHdG quantification by ELISA in cGAS or NLRP3 immunocomplexes isolated from Mito + RBC-activated BLaER1 Mo. (n=3). e, Experimental scheme (left) and DB analysis (right) of IP cGAS or NLRP3 upon incubation with biotinylated intact (Int) or fragmented (Fgt) mtDNA. As a loading control, cGAS or NLRP3 immunoblot was performed. f, SDD-AGE of MAVS oligomerization in BLaER1 Mo in response to Mito + RBCs (generated with or without Act D) or to transfection with Poly I:C. One representative of three. g, Western blot analysis confirming CRISPR/Cas9-mediated KO of MAVS. h, Relative caspase-1 activity in the lysate of Mito + RBC-activated wild type, MAVS or RIG-I/MDA5 KOBLaER1 Mo. (n=3). i, Normalized IL-1β levels in the supernatants of Poly I:C/Lyovec-activated BLaER1 Mo in the presence of MCC950 or Ac-YVAD-cmk or that were generated in the presence of EtBr. (n=3). j, Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Poly I:C/Lyovec-activated wild type or MAVS KO BLaER1 Mo. (n=3). k, Relative caspase-1 activity in the lysate of Poly I:C/Lyovec-activated wild type, MAVS or RIG-I/MDA5 KO BLaER1 Mo. (n=3).
    Figure Legend Snippet: a, Western blot analysis confirming CRISPR/Cas9-mediated KO of mitochondrial DNA polymerase gamma (POLG; Polγ). b, Normalized IL-1β levels in the supernatants of Mito + RBC-activated wild type or POLG KO BLaER1 Mo. (n=3). c, DB analysis of cGAS or NLRP3 immunocomplexes isolated from Mito + RBCs-activated BLaER1 Mo. As a loading control, dsDNA dot blot (DB) was performed. d, 8-OHdG quantification by ELISA in cGAS or NLRP3 immunocomplexes isolated from Mito + RBC-activated BLaER1 Mo. (n=3). e, Experimental scheme (left) and DB analysis (right) of IP cGAS or NLRP3 upon incubation with biotinylated intact (Int) or fragmented (Fgt) mtDNA. As a loading control, cGAS or NLRP3 immunoblot was performed. f, SDD-AGE of MAVS oligomerization in BLaER1 Mo in response to Mito + RBCs (generated with or without Act D) or to transfection with Poly I:C. One representative of three. g, Western blot analysis confirming CRISPR/Cas9-mediated KO of MAVS. h, Relative caspase-1 activity in the lysate of Mito + RBC-activated wild type, MAVS or RIG-I/MDA5 KOBLaER1 Mo. (n=3). i, Normalized IL-1β levels in the supernatants of Poly I:C/Lyovec-activated BLaER1 Mo in the presence of MCC950 or Ac-YVAD-cmk or that were generated in the presence of EtBr. (n=3). j, Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Poly I:C/Lyovec-activated wild type or MAVS KO BLaER1 Mo. (n=3). k, Relative caspase-1 activity in the lysate of Poly I:C/Lyovec-activated wild type, MAVS or RIG-I/MDA5 KO BLaER1 Mo. (n=3).

    Techniques Used: Western Blot, CRISPR, Isolation, Control, Dot Blot, Enzyme-linked Immunosorbent Assay, Incubation, Generated, Transfection, Activity Assay

    a, Western blot analysis confirming CRISPR/Cas9-mediated KO of RIG-I or MDA5. b, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type, RIG-I KO or MDA5 KO BLaER1 Mo. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of DHX33. d, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type or DHX33 KO BLaER1 Mo. (n=3). e, Western blot analysis confirming CRISPR/Cas9-mediated KO of both RIG-I and MDA5. Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Mito + RBCs (f) or Poly I:C/Lyovec (g) activated wild type or RIG-I/MDA5 KO BLaER1 Mo. (n=3).
    Figure Legend Snippet: a, Western blot analysis confirming CRISPR/Cas9-mediated KO of RIG-I or MDA5. b, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type, RIG-I KO or MDA5 KO BLaER1 Mo. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of DHX33. d, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type or DHX33 KO BLaER1 Mo. (n=3). e, Western blot analysis confirming CRISPR/Cas9-mediated KO of both RIG-I and MDA5. Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Mito + RBCs (f) or Poly I:C/Lyovec (g) activated wild type or RIG-I/MDA5 KO BLaER1 Mo. (n=3).

    Techniques Used: Western Blot, CRISPR, Isolation

    a, Western blot analysis of gasdermin-D N-terminal fragment (GSDMD-NT) in total cell lysate isolated from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated BLaER1 Mo. b , Quantification of lactate dehydrogenase (LDH) release or propidium iodide (PI) internalization in BLaER1 Mo activated Mito + RBCs, Poly I:C/Lyovec or Nigericin over time. Data are normalized to media-treated cells. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of GSDMD (left). Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated wild type or GSDMD KO BLaER1 Mo (right). (n=3). Confocal images of classical Mo isolated from SLE patients and stained for IL-1β and ISG15 (d) or IFIT1 (e). Scale bar: 15 µm.
    Figure Legend Snippet: a, Western blot analysis of gasdermin-D N-terminal fragment (GSDMD-NT) in total cell lysate isolated from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated BLaER1 Mo. b , Quantification of lactate dehydrogenase (LDH) release or propidium iodide (PI) internalization in BLaER1 Mo activated Mito + RBCs, Poly I:C/Lyovec or Nigericin over time. Data are normalized to media-treated cells. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of GSDMD (left). Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated wild type or GSDMD KO BLaER1 Mo (right). (n=3). Confocal images of classical Mo isolated from SLE patients and stained for IL-1β and ISG15 (d) or IFIT1 (e). Scale bar: 15 µm.

    Techniques Used: Western Blot, Isolation, CRISPR, Staining

    a, Experimental scheme (left) and Western blot analysis (right) of the microsomal pellet (100k P) and postmicrosomal supernatant (100k S) isolated from Poly I:C/Lyovec-activated BLaER1 Mo. b , Western blot analysis of different fractions collected after sucrose fractionation of microsomal membranes isolated from Poly I:C/Lyovec-activated BLaER1 Mo. ER: endoplasmic reticulum; ERGIC: ER-Golgi intermediate compartment. c, Western blot analysis of the 100k P and 100k S fractions isolated from Poly I:C/Lyovec-activated wild type or MxA KOBLaER1 Mo. d, Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and dsDNA/Lyovec-activated wild type or MxA KO BLaER1 Mo. (n=3).
    Figure Legend Snippet: a, Experimental scheme (left) and Western blot analysis (right) of the microsomal pellet (100k P) and postmicrosomal supernatant (100k S) isolated from Poly I:C/Lyovec-activated BLaER1 Mo. b , Western blot analysis of different fractions collected after sucrose fractionation of microsomal membranes isolated from Poly I:C/Lyovec-activated BLaER1 Mo. ER: endoplasmic reticulum; ERGIC: ER-Golgi intermediate compartment. c, Western blot analysis of the 100k P and 100k S fractions isolated from Poly I:C/Lyovec-activated wild type or MxA KOBLaER1 Mo. d, Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and dsDNA/Lyovec-activated wild type or MxA KO BLaER1 Mo. (n=3).

    Techniques Used: Western Blot, Isolation, Fractionation

    a, Immunoblot analysis of mIL-1β present within liposomes (pellet), or supernatants (sup) after ultracentrifugation of liposomes that were treated with buffer or recombinant human MxA for 0 (control), 30 and 120 min. Densitometry quantification of Western blot band density for mIL-1β release from liposomes is also shown. (n=3). b, Quantification of LDH enzymatic activity release from Lp loaded with LDH and treated with buffer or MxA for indicated times. (n=3). c, Normalized IL-1β levels in the supernatants from Mito + RBCs-activated BLaER1 Mo with the indicated genotype. (n=3). Immunoblot analysis of the total cell lysate is also shown. d, Western blot analysis confirming Trim-Away knockdown of MxA (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of MxA (right). (n=3). e, Western blot analysis of whole cell lysate (WCL) and supernatants (Sup) isolated from BLaER1 Mo overexpressing mIL-1β that were treated with or without recombinant Type I IFN (IFNα2β). One representative of two.
    Figure Legend Snippet: a, Immunoblot analysis of mIL-1β present within liposomes (pellet), or supernatants (sup) after ultracentrifugation of liposomes that were treated with buffer or recombinant human MxA for 0 (control), 30 and 120 min. Densitometry quantification of Western blot band density for mIL-1β release from liposomes is also shown. (n=3). b, Quantification of LDH enzymatic activity release from Lp loaded with LDH and treated with buffer or MxA for indicated times. (n=3). c, Normalized IL-1β levels in the supernatants from Mito + RBCs-activated BLaER1 Mo with the indicated genotype. (n=3). Immunoblot analysis of the total cell lysate is also shown. d, Western blot analysis confirming Trim-Away knockdown of MxA (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of MxA (right). (n=3). e, Western blot analysis of whole cell lysate (WCL) and supernatants (Sup) isolated from BLaER1 Mo overexpressing mIL-1β that were treated with or without recombinant Type I IFN (IFNα2β). One representative of two.

    Techniques Used: Western Blot, Liposomes, Recombinant, Control, Activity Assay, Knockdown, Isolation

    (1) In SLE patients with active disease, internalization of Mito + RBCs induces Mo to co-express ISGs and mIL-1β. ISG expression depends on cGAS activation by Mito + RBC-derived mtDNA (2), while mIL-1β production requires NLRP3 activation. Upstream of NLRP3, Mito + RBC-derived mt dsRNA activates the RLRs/MAVS pathway, which induces the release of Mo-derived mtDNA fragments that bind NLRP3 (3). Importantly, mIL-1β triggers the oligomerization of MxA on the surface or the TGN (4), which favors the entry of this cytokine into a TGN-mediated unconventional secretory (vesicular?) pathway (5). (6) Cytosolic dsRNA of microbial origin (i.e. Poly I:C/Lyovec) could also activate these pathways via MAVS/IRF3.
    Figure Legend Snippet: (1) In SLE patients with active disease, internalization of Mito + RBCs induces Mo to co-express ISGs and mIL-1β. ISG expression depends on cGAS activation by Mito + RBC-derived mtDNA (2), while mIL-1β production requires NLRP3 activation. Upstream of NLRP3, Mito + RBC-derived mt dsRNA activates the RLRs/MAVS pathway, which induces the release of Mo-derived mtDNA fragments that bind NLRP3 (3). Importantly, mIL-1β triggers the oligomerization of MxA on the surface or the TGN (4), which favors the entry of this cytokine into a TGN-mediated unconventional secretory (vesicular?) pathway (5). (6) Cytosolic dsRNA of microbial origin (i.e. Poly I:C/Lyovec) could also activate these pathways via MAVS/IRF3.

    Techniques Used: Expressing, Activation Assay, Derivative Assay

    Related Articles

    Cell Culture:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Isolation:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Staining:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Two Tailed Test:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Labeling:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Western Blot:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Generated:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Immunoprecipitation:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Control:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Dot Blot:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    CRISPR:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Flow Cytometry:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Electroporation:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Knockdown:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Enzyme-linked Immunosorbent Assay:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Incubation:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Transfection:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Activity Assay:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Fractionation:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Liposomes:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Recombinant:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Expressing:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Activation Assay:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Derivative Assay:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    DNA Extraction:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Picogreen Assay:

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes
    Article Snippet: Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.Cells were kept between 2−4×10 6 cells/mL by daily counting and medium changes.. To generate Mito + RBCs, MG132 (5 mM; Santa Cruz Biotech) was added to the culture during phase 3.. To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.



    Similar Products

    96
    Santa Cruz Biotechnology mito rbcs
    a, Confocal images (left) and quantification (right) of classical Mo isolated from JDM and SLE patients. Each dot represents the average count from at least ten different micrscopy fields from a study participant sample that was processed, stained and analyzed independently. Scale bar: 20 µm. b, Percentage of IL-1β − MxA + Mo and IL-1β + MxA + Mo in SLE patients without (blue, n=8) or with (red, n=6) circulating <t>Mito</t> + <t>RBCs.</t> c, Confocal images of classical Mo isolated from SLE patients showing evidence of erythrophagocytosis. GPA: Glycophorin A. Scale bar: 20 µm. d, Two-tailed Pearson’s correlation between SLEDAI and the percentage of IL-1β + ISGs + Mo (n=20). Dashed lines represent 95% confidence intervals. Each dot represents a study participant sample that was processed, stained and analyzed independently.
    Mito Rbcs, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mito+rbcs/MG-132/bio_rxiv__2023__08__03__551696-216-3-13
    Average 96 stars, based on 1 article reviews
    mito rbcs - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    Image Search Results


    a, Confocal images (left) and quantification (right) of classical Mo isolated from JDM and SLE patients. Each dot represents the average count from at least ten different micrscopy fields from a study participant sample that was processed, stained and analyzed independently. Scale bar: 20 µm. b, Percentage of IL-1β − MxA + Mo and IL-1β + MxA + Mo in SLE patients without (blue, n=8) or with (red, n=6) circulating Mito + RBCs. c, Confocal images of classical Mo isolated from SLE patients showing evidence of erythrophagocytosis. GPA: Glycophorin A. Scale bar: 20 µm. d, Two-tailed Pearson’s correlation between SLEDAI and the percentage of IL-1β + ISGs + Mo (n=20). Dashed lines represent 95% confidence intervals. Each dot represents a study participant sample that was processed, stained and analyzed independently.

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Confocal images (left) and quantification (right) of classical Mo isolated from JDM and SLE patients. Each dot represents the average count from at least ten different micrscopy fields from a study participant sample that was processed, stained and analyzed independently. Scale bar: 20 µm. b, Percentage of IL-1β − MxA + Mo and IL-1β + MxA + Mo in SLE patients without (blue, n=8) or with (red, n=6) circulating Mito + RBCs. c, Confocal images of classical Mo isolated from SLE patients showing evidence of erythrophagocytosis. GPA: Glycophorin A. Scale bar: 20 µm. d, Two-tailed Pearson’s correlation between SLEDAI and the percentage of IL-1β + ISGs + Mo (n=20). Dashed lines represent 95% confidence intervals. Each dot represents a study participant sample that was processed, stained and analyzed independently.

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Isolation, Staining, Two Tailed Test

    a, Phagocytosis of CFSE-labeled RBCs in the presence or absence of IgG opsonizing antibodies. b, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by blood Mo. (n=3). c, Immunoblot analysis of whole cell lysate (WCL) and supernatants (Sup) from blood Mo that were treated as described. One representative of two experiments. d, Levels of IP-10 and IL-1β in the supernatants of bone marrow (BM) Mo cultured with media, Mito - or Mito + opsonized RBCs. (n=3). e, Phenotype of BLaER1 cells before (Day 1) and after (Day 6) differentiation into BLaER1 Mo. f, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by BLaER1 Mo. (n=3). g, Immunoblot analysis of WCL and Sup from BLaER1 Mo that were treated as described. One representative of two. h, Relative mtDNA abundance in Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. (n=3). i, Quantification of phagocytosis of CFSE-labeled Mito + RBCs RBCs generated with vehicle or EtBr (ρ 0 ). (n=3). j, Western blot analysis of Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. One representative of two.

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Phagocytosis of CFSE-labeled RBCs in the presence or absence of IgG opsonizing antibodies. b, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by blood Mo. (n=3). c, Immunoblot analysis of whole cell lysate (WCL) and supernatants (Sup) from blood Mo that were treated as described. One representative of two experiments. d, Levels of IP-10 and IL-1β in the supernatants of bone marrow (BM) Mo cultured with media, Mito - or Mito + opsonized RBCs. (n=3). e, Phenotype of BLaER1 cells before (Day 1) and after (Day 6) differentiation into BLaER1 Mo. f, Quantification of phagocytosis of CFSE-labeled Mito - or Mito + RBCs by BLaER1 Mo. (n=3). g, Immunoblot analysis of WCL and Sup from BLaER1 Mo that were treated as described. One representative of two. h, Relative mtDNA abundance in Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. (n=3). i, Quantification of phagocytosis of CFSE-labeled Mito + RBCs RBCs generated with vehicle or EtBr (ρ 0 ). (n=3). j, Western blot analysis of Mito + RBCs generated with vehicle, EtBr (ρ 0 ) or CAM. One representative of two.

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Labeling, Western Blot, Cell Culture, Generated

    a, Heat map of differentially expressed genes in blood Mo that phagocytized either Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . b, Levels of IP-10 and IL-1β in the supernatants of blood Mo cultured with media, Mito - or Mito + RBCs. (n=6). c, Heat map of differentially expressed genes in BLaER1 Mo that phagocytized Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . d, Levels of IP-10 and IL-1β in the supernatants of BLaER1 Mo cultured with media, Mito - or Mito + RBCs. (n=4). e, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo activated with Mito + RBCs generated in the presence of vehicle, ethidium bromide (EtBr; ρ 0 ) or chloramphenicol (CAM). (n=4).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Heat map of differentially expressed genes in blood Mo that phagocytized either Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . b, Levels of IP-10 and IL-1β in the supernatants of blood Mo cultured with media, Mito - or Mito + RBCs. (n=6). c, Heat map of differentially expressed genes in BLaER1 Mo that phagocytized Mito - or Mito + RBCs. Data are normalized to Mito - RBCs sample . d, Levels of IP-10 and IL-1β in the supernatants of BLaER1 Mo cultured with media, Mito - or Mito + RBCs. (n=4). e, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo activated with Mito + RBCs generated in the presence of vehicle, ethidium bromide (EtBr; ρ 0 ) or chloramphenicol (CAM). (n=4).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Cell Culture, Generated

    a, Normalized IP-10 levels in the supernatants of Mito + RBCs-activated wild type, cGAS KOor STING1 KO BLaER1 Mo. (n=3). b, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or Caspase-1 KO BLaER1 Mo. (n=3). c, Experimental scheme (left), dot/Western blot analysis (middle) and quantification (left; n=3) of Mito + RBCs (1 - 3) or BLaER1 Mo (2 − 4) labeled with bromodeoxyuridine (BrdU) and then immunoprecipitated (IP) with cGAS or NLRP3 antibodies. As a loading control, cGAS or NLRP3 immunoblot or double-stranded DNA (dsDNA) dot blot (DB) was performed. A.U.: Arbitrary Units.

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Normalized IP-10 levels in the supernatants of Mito + RBCs-activated wild type, cGAS KOor STING1 KO BLaER1 Mo. (n=3). b, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or Caspase-1 KO BLaER1 Mo. (n=3). c, Experimental scheme (left), dot/Western blot analysis (middle) and quantification (left; n=3) of Mito + RBCs (1 - 3) or BLaER1 Mo (2 − 4) labeled with bromodeoxyuridine (BrdU) and then immunoprecipitated (IP) with cGAS or NLRP3 antibodies. As a loading control, cGAS or NLRP3 immunoblot or double-stranded DNA (dsDNA) dot blot (DB) was performed. A.U.: Arbitrary Units.

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot, Labeling, Immunoprecipitation, Control, Dot Blot

    a, Western blot analysis confirming CRISPR/Cas9-mediated KO of cGAS and STING1. b, Normalized IP-10 levels in the supernatants of Mito + RBC-activated BLaER1 Mo in the presence of the cGAS inhibitor RU.521 or the STING inhibitor H151. (n=3). c, Western blot analysis of phosphorylated TBK1 and IRF3 in BLaER1 Mo cultured with media or Mito + RBCs. d, Western blot analysis confirming CRISPR/Cas9-mediated KO of AIM2. e, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or AIM2 KO BLaER1 Mo. (n=3). f, Flow cytometry analysis showing the internalization of unlabeled (control) or AlexaFluor 488 (AF488)-labeld IgG upon electroporation. g, Percentages of cell death measured by 7AAD incorporation. h, Western blot analysis confirming Trim-Away knockdown of AIM2 (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of AIM2 (right). (n=3). i, Western blot analysis confirming CRISPR/Cas9-mediated KO of Caspase-1. j, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated BLaER1 Mo in the presence of the NLRP3 inhibitor MCC950 or the caspase-1 inhibitor Ac-YVAD-cmk. (n=4). k, Phagocytosis of CFSE-labeled RBCs in wild type, cGAS KO, STING1 KO or caspase-1 KO BLaER1 Mo. (n=3).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Western blot analysis confirming CRISPR/Cas9-mediated KO of cGAS and STING1. b, Normalized IP-10 levels in the supernatants of Mito + RBC-activated BLaER1 Mo in the presence of the cGAS inhibitor RU.521 or the STING inhibitor H151. (n=3). c, Western blot analysis of phosphorylated TBK1 and IRF3 in BLaER1 Mo cultured with media or Mito + RBCs. d, Western blot analysis confirming CRISPR/Cas9-mediated KO of AIM2. e, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated wild type or AIM2 KO BLaER1 Mo. (n=3). f, Flow cytometry analysis showing the internalization of unlabeled (control) or AlexaFluor 488 (AF488)-labeld IgG upon electroporation. g, Percentages of cell death measured by 7AAD incorporation. h, Western blot analysis confirming Trim-Away knockdown of AIM2 (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of AIM2 (right). (n=3). i, Western blot analysis confirming CRISPR/Cas9-mediated KO of Caspase-1. j, Normalized IL-1β levels in the supernatants of Mito + RBCs-activated BLaER1 Mo in the presence of the NLRP3 inhibitor MCC950 or the caspase-1 inhibitor Ac-YVAD-cmk. (n=4). k, Phagocytosis of CFSE-labeled RBCs in wild type, cGAS KO, STING1 KO or caspase-1 KO BLaER1 Mo. (n=3).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot, CRISPR, Cell Culture, Flow Cytometry, Control, Electroporation, Knockdown, Labeling

    a, Normalized cytokine levels in the supernatants of blood Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. b, Normalized cytokine levels in the supernatants of Mito + RBC-activated blood Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3). c, Normalized cytokine levels in the supernatants of BM Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. d, Normalized cytokine levels in the supernatants of Mito + RBCs-activated BM Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Normalized cytokine levels in the supernatants of blood Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. b, Normalized cytokine levels in the supernatants of Mito + RBC-activated blood Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3). c, Normalized cytokine levels in the supernatants of BM Mo activated with Mito + RBCs generated in the presence of vehicle, EtBr (ρ 0 ) or CAM. d, Normalized cytokine levels in the supernatants of Mito + RBCs-activated BM Mo in the presence of RU.521, H151, MCC950 or Ac-YVAD-cmk. (n=3).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Generated

    a, Western blot analysis of cytosolic fraction obtained from media, Mito + RBCs- or dsDNA/Lyovec-activated BLaER1 Mo. WCL: whole cell lysate. Quantification of lactate dehydrogenase (LDH) release (b) or propidium iodide (PI) internalization (c) in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec over time. Data are normalized to media-treated cells. (n=3). d, Western blot analysis of ASC oligomers (pyroptosome) formation in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec for 18 h. Triton X-100 soluble (TX100 Sol ) and insoluble (TX100 Ins ) fractions were immunoblotted with ASC antibody. One representative of two experiments. e, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of the lysosmal acidification inhibitor Bafilomycin A1 (BAf A1). (n=3). f, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of extracellular K + . (n=3).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Western blot analysis of cytosolic fraction obtained from media, Mito + RBCs- or dsDNA/Lyovec-activated BLaER1 Mo. WCL: whole cell lysate. Quantification of lactate dehydrogenase (LDH) release (b) or propidium iodide (PI) internalization (c) in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec over time. Data are normalized to media-treated cells. (n=3). d, Western blot analysis of ASC oligomers (pyroptosome) formation in BLaER1 Mo activated Mito + RBCs or dsDNA/Lyovec for 18 h. Triton X-100 soluble (TX100 Sol ) and insoluble (TX100 Ins ) fractions were immunoblotted with ASC antibody. One representative of two experiments. e, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of the lysosmal acidification inhibitor Bafilomycin A1 (BAf A1). (n=3). f, Normalized IL-1β levels in the supernatants of Mito + RBC- or dsDNA/Lyovec-activated BLaER1 Mo in the presence of extracellular K + . (n=3).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot

    a, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo, generated in the presence of vehicle, EtBr (ρ 0 ) or CAM and activated with Mito + RBCs. (n=4). b, Relative levels of mtDNA-encoded genes in cGAS (left) or NLRP3 (right) immunocomplexes isolated from Mito + RBC-activated wild type or MAVS KO BLaER1 Mo. (n=3). c, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo cultured with Mito + RBCs generated in the presence of Actinomycin D (Act D). (n=4). d, Normalized IL-1β levels in the supernatants of Mito + RBCs- or Poly I:C/Lyovec-activated wild type, MAVS KO or RIG- I/MDA5 KO BLaER1 Mo. (n=3).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo, generated in the presence of vehicle, EtBr (ρ 0 ) or CAM and activated with Mito + RBCs. (n=4). b, Relative levels of mtDNA-encoded genes in cGAS (left) or NLRP3 (right) immunocomplexes isolated from Mito + RBC-activated wild type or MAVS KO BLaER1 Mo. (n=3). c, Experiment scheme (left) and normalized cytokine levels (right) in the supernatants of BLaER1 Mo cultured with Mito + RBCs generated in the presence of Actinomycin D (Act D). (n=4). d, Normalized IL-1β levels in the supernatants of Mito + RBCs- or Poly I:C/Lyovec-activated wild type, MAVS KO or RIG- I/MDA5 KO BLaER1 Mo. (n=3).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Generated, Isolation, Cell Culture

    a, Western blot analysis confirming CRISPR/Cas9-mediated KO of mitochondrial DNA polymerase gamma (POLG; Polγ). b, Normalized IL-1β levels in the supernatants of Mito + RBC-activated wild type or POLG KO BLaER1 Mo. (n=3). c, DB analysis of cGAS or NLRP3 immunocomplexes isolated from Mito + RBCs-activated BLaER1 Mo. As a loading control, dsDNA dot blot (DB) was performed. d, 8-OHdG quantification by ELISA in cGAS or NLRP3 immunocomplexes isolated from Mito + RBC-activated BLaER1 Mo. (n=3). e, Experimental scheme (left) and DB analysis (right) of IP cGAS or NLRP3 upon incubation with biotinylated intact (Int) or fragmented (Fgt) mtDNA. As a loading control, cGAS or NLRP3 immunoblot was performed. f, SDD-AGE of MAVS oligomerization in BLaER1 Mo in response to Mito + RBCs (generated with or without Act D) or to transfection with Poly I:C. One representative of three. g, Western blot analysis confirming CRISPR/Cas9-mediated KO of MAVS. h, Relative caspase-1 activity in the lysate of Mito + RBC-activated wild type, MAVS or RIG-I/MDA5 KOBLaER1 Mo. (n=3). i, Normalized IL-1β levels in the supernatants of Poly I:C/Lyovec-activated BLaER1 Mo in the presence of MCC950 or Ac-YVAD-cmk or that were generated in the presence of EtBr. (n=3). j, Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Poly I:C/Lyovec-activated wild type or MAVS KO BLaER1 Mo. (n=3). k, Relative caspase-1 activity in the lysate of Poly I:C/Lyovec-activated wild type, MAVS or RIG-I/MDA5 KO BLaER1 Mo. (n=3).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Western blot analysis confirming CRISPR/Cas9-mediated KO of mitochondrial DNA polymerase gamma (POLG; Polγ). b, Normalized IL-1β levels in the supernatants of Mito + RBC-activated wild type or POLG KO BLaER1 Mo. (n=3). c, DB analysis of cGAS or NLRP3 immunocomplexes isolated from Mito + RBCs-activated BLaER1 Mo. As a loading control, dsDNA dot blot (DB) was performed. d, 8-OHdG quantification by ELISA in cGAS or NLRP3 immunocomplexes isolated from Mito + RBC-activated BLaER1 Mo. (n=3). e, Experimental scheme (left) and DB analysis (right) of IP cGAS or NLRP3 upon incubation with biotinylated intact (Int) or fragmented (Fgt) mtDNA. As a loading control, cGAS or NLRP3 immunoblot was performed. f, SDD-AGE of MAVS oligomerization in BLaER1 Mo in response to Mito + RBCs (generated with or without Act D) or to transfection with Poly I:C. One representative of three. g, Western blot analysis confirming CRISPR/Cas9-mediated KO of MAVS. h, Relative caspase-1 activity in the lysate of Mito + RBC-activated wild type, MAVS or RIG-I/MDA5 KOBLaER1 Mo. (n=3). i, Normalized IL-1β levels in the supernatants of Poly I:C/Lyovec-activated BLaER1 Mo in the presence of MCC950 or Ac-YVAD-cmk or that were generated in the presence of EtBr. (n=3). j, Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Poly I:C/Lyovec-activated wild type or MAVS KO BLaER1 Mo. (n=3). k, Relative caspase-1 activity in the lysate of Poly I:C/Lyovec-activated wild type, MAVS or RIG-I/MDA5 KO BLaER1 Mo. (n=3).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot, CRISPR, Isolation, Control, Dot Blot, Enzyme-linked Immunosorbent Assay, Incubation, Generated, Transfection, Activity Assay

    a, Western blot analysis confirming CRISPR/Cas9-mediated KO of RIG-I or MDA5. b, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type, RIG-I KO or MDA5 KO BLaER1 Mo. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of DHX33. d, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type or DHX33 KO BLaER1 Mo. (n=3). e, Western blot analysis confirming CRISPR/Cas9-mediated KO of both RIG-I and MDA5. Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Mito + RBCs (f) or Poly I:C/Lyovec (g) activated wild type or RIG-I/MDA5 KO BLaER1 Mo. (n=3).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Western blot analysis confirming CRISPR/Cas9-mediated KO of RIG-I or MDA5. b, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type, RIG-I KO or MDA5 KO BLaER1 Mo. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of DHX33. d, Normalized IL-1β levels in the supernatants of Mito + RBCs or Poly I:C/Lyovec-activated wild type or DHX33 KO BLaER1 Mo. (n=3). e, Western blot analysis confirming CRISPR/Cas9-mediated KO of both RIG-I and MDA5. Relative levels of mtDNA-encoded genes in NLRP3 immunocomplexes isolated from Mito + RBCs (f) or Poly I:C/Lyovec (g) activated wild type or RIG-I/MDA5 KO BLaER1 Mo. (n=3).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot, CRISPR, Isolation

    a, Western blot analysis of gasdermin-D N-terminal fragment (GSDMD-NT) in total cell lysate isolated from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated BLaER1 Mo. b , Quantification of lactate dehydrogenase (LDH) release or propidium iodide (PI) internalization in BLaER1 Mo activated Mito + RBCs, Poly I:C/Lyovec or Nigericin over time. Data are normalized to media-treated cells. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of GSDMD (left). Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated wild type or GSDMD KO BLaER1 Mo (right). (n=3). Confocal images of classical Mo isolated from SLE patients and stained for IL-1β and ISG15 (d) or IFIT1 (e). Scale bar: 15 µm.

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Western blot analysis of gasdermin-D N-terminal fragment (GSDMD-NT) in total cell lysate isolated from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated BLaER1 Mo. b , Quantification of lactate dehydrogenase (LDH) release or propidium iodide (PI) internalization in BLaER1 Mo activated Mito + RBCs, Poly I:C/Lyovec or Nigericin over time. Data are normalized to media-treated cells. (n=3). c, Western blot analysis confirming CRISPR/Cas9-mediated KO of GSDMD (left). Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and Nigericin-activated wild type or GSDMD KO BLaER1 Mo (right). (n=3). Confocal images of classical Mo isolated from SLE patients and stained for IL-1β and ISG15 (d) or IFIT1 (e). Scale bar: 15 µm.

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot, Isolation, CRISPR, Staining

    a, Experimental scheme (left) and Western blot analysis (right) of the microsomal pellet (100k P) and postmicrosomal supernatant (100k S) isolated from Poly I:C/Lyovec-activated BLaER1 Mo. b , Western blot analysis of different fractions collected after sucrose fractionation of microsomal membranes isolated from Poly I:C/Lyovec-activated BLaER1 Mo. ER: endoplasmic reticulum; ERGIC: ER-Golgi intermediate compartment. c, Western blot analysis of the 100k P and 100k S fractions isolated from Poly I:C/Lyovec-activated wild type or MxA KOBLaER1 Mo. d, Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and dsDNA/Lyovec-activated wild type or MxA KO BLaER1 Mo. (n=3).

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Experimental scheme (left) and Western blot analysis (right) of the microsomal pellet (100k P) and postmicrosomal supernatant (100k S) isolated from Poly I:C/Lyovec-activated BLaER1 Mo. b , Western blot analysis of different fractions collected after sucrose fractionation of microsomal membranes isolated from Poly I:C/Lyovec-activated BLaER1 Mo. ER: endoplasmic reticulum; ERGIC: ER-Golgi intermediate compartment. c, Western blot analysis of the 100k P and 100k S fractions isolated from Poly I:C/Lyovec-activated wild type or MxA KOBLaER1 Mo. d, Normalized IL-1β levels in the supernatants from Mito + RBCs, Poly I:C/Lyovec and dsDNA/Lyovec-activated wild type or MxA KO BLaER1 Mo. (n=3).

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot, Isolation, Fractionation

    a, Immunoblot analysis of mIL-1β present within liposomes (pellet), or supernatants (sup) after ultracentrifugation of liposomes that were treated with buffer or recombinant human MxA for 0 (control), 30 and 120 min. Densitometry quantification of Western blot band density for mIL-1β release from liposomes is also shown. (n=3). b, Quantification of LDH enzymatic activity release from Lp loaded with LDH and treated with buffer or MxA for indicated times. (n=3). c, Normalized IL-1β levels in the supernatants from Mito + RBCs-activated BLaER1 Mo with the indicated genotype. (n=3). Immunoblot analysis of the total cell lysate is also shown. d, Western blot analysis confirming Trim-Away knockdown of MxA (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of MxA (right). (n=3). e, Western blot analysis of whole cell lysate (WCL) and supernatants (Sup) isolated from BLaER1 Mo overexpressing mIL-1β that were treated with or without recombinant Type I IFN (IFNα2β). One representative of two.

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: a, Immunoblot analysis of mIL-1β present within liposomes (pellet), or supernatants (sup) after ultracentrifugation of liposomes that were treated with buffer or recombinant human MxA for 0 (control), 30 and 120 min. Densitometry quantification of Western blot band density for mIL-1β release from liposomes is also shown. (n=3). b, Quantification of LDH enzymatic activity release from Lp loaded with LDH and treated with buffer or MxA for indicated times. (n=3). c, Normalized IL-1β levels in the supernatants from Mito + RBCs-activated BLaER1 Mo with the indicated genotype. (n=3). Immunoblot analysis of the total cell lysate is also shown. d, Western blot analysis confirming Trim-Away knockdown of MxA (left). Normalized IL-1β levels in the supernatants of activated BLaER1 Mo upon Trim-Away knockdown of MxA (right). (n=3). e, Western blot analysis of whole cell lysate (WCL) and supernatants (Sup) isolated from BLaER1 Mo overexpressing mIL-1β that were treated with or without recombinant Type I IFN (IFNα2β). One representative of two.

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Western Blot, Liposomes, Recombinant, Control, Activity Assay, Knockdown, Isolation

    (1) In SLE patients with active disease, internalization of Mito + RBCs induces Mo to co-express ISGs and mIL-1β. ISG expression depends on cGAS activation by Mito + RBC-derived mtDNA (2), while mIL-1β production requires NLRP3 activation. Upstream of NLRP3, Mito + RBC-derived mt dsRNA activates the RLRs/MAVS pathway, which induces the release of Mo-derived mtDNA fragments that bind NLRP3 (3). Importantly, mIL-1β triggers the oligomerization of MxA on the surface or the TGN (4), which favors the entry of this cytokine into a TGN-mediated unconventional secretory (vesicular?) pathway (5). (6) Cytosolic dsRNA of microbial origin (i.e. Poly I:C/Lyovec) could also activate these pathways via MAVS/IRF3.

    Journal: bioRxiv

    Article Title: An unconventional mechanism of IL-1β secretion that requires Type I IFN in lupus monocytes

    doi: 10.1101/2023.08.03.551696

    Figure Lengend Snippet: (1) In SLE patients with active disease, internalization of Mito + RBCs induces Mo to co-express ISGs and mIL-1β. ISG expression depends on cGAS activation by Mito + RBC-derived mtDNA (2), while mIL-1β production requires NLRP3 activation. Upstream of NLRP3, Mito + RBC-derived mt dsRNA activates the RLRs/MAVS pathway, which induces the release of Mo-derived mtDNA fragments that bind NLRP3 (3). Importantly, mIL-1β triggers the oligomerization of MxA on the surface or the TGN (4), which favors the entry of this cytokine into a TGN-mediated unconventional secretory (vesicular?) pathway (5). (6) Cytosolic dsRNA of microbial origin (i.e. Poly I:C/Lyovec) could also activate these pathways via MAVS/IRF3.

    Article Snippet: To generate ρ° Mito + RBCs, cells were cultured with MG132 (5 mM; Santa Cruz Biotech) and 500 ng/mL of ethidium bromide (EtBr; Sigma−Aldrich) during phase 3 and checked for mitochondrial and nuclear DNA content by RT-PCR.

    Techniques: Expressing, Activation Assay, Derivative Assay